Skip to main content
Log in

Anti-TNF strategies in stenosing and fistulizing Crohn’s disease

International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Background

Stenoses and fistulas are frequent complications in patients with Crohn’s disease (CD). They represent a major diagnostic and therapeutic challenge and surgical intervention is often required. The availability of novel, anti-TNF strategies for therapy has raised the question as to what extent these new treatment options have impact on the clinical decision-making process regarding the necessity for surgery.

Discussion

A short overview of the current pathophysiological understanding of CD, focusing on the immunology of the intestinal mucosa, is given. Then the problems of proper clinical management of stenoses and fistulas are addressed. With regard to symptomatic stenoses, attention will be given to novel diagnostic tools for the distinction between inflammatory and fibrotic stenoses, and our clinical experience with the treatment of symptomatic inflammatory stenoses with infliximab will be discussed. With regard to fistulizing CD, the data that are currently available for medical therapy are summarized with special reference to the studies on the efficacy of anti-TNF treatment.

Conclusion

With regard to moderately and severe inflammatory stenoses, medical treatment with infliximab may be an option after careful assessment of the inflammatory nature of the stenosis and exclusion of a septic focus. With regard to fistulas, anti-TNF treatment is a valuable option that is likely to improve the clinical outcome. Based on the available data, however, anti-TNF treatment cannot yet replace surgical intervention when necessary. Prospective trials of medical therapy and a combination of medical and surgical therapy for complex fistulas and internal fistulas are needed to define the potential and the limitations of these novel therapeutic approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Shivananda S et al (1996) Incidence of inflammatory bowel disease across Europe. Is there a difference between North and South. Gut 39:690–697

    CAS  PubMed  Google Scholar 

  2. Farmer RG, Hawk WA, Turnbull RBJ (1975) National cooperative Crohn’s disease study: extraintestinal manifestations and perianal complications. Gastroenterology 77:914–920

    Google Scholar 

  3. Steinberg DM, Cooke WT, Alexander-Williams J (1973) Abscess and fistulae in Crohn’s disease. Gut 14:865–869

    CAS  PubMed  Google Scholar 

  4. Holtmann M et al (2002) Das mukosale Immunsystem. Wie klar ist die Pathogenese. Internist 43:1343–1353

    Article  CAS  PubMed  Google Scholar 

  5. Hugot JP et al (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 411:599–603

    Article  CAS  PubMed  Google Scholar 

  6. Ogura Y et al (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 411:603–606

    Article  CAS  PubMed  Google Scholar 

  7. Neurath MF, Finotto S, Glimcher LH (2002) The role of Th1/Th2 polarization in mucosal immunity. Nat Med 8:567–573

    Article  CAS  PubMed  Google Scholar 

  8. Holtmann M et al (2002) Functional relevance of soluble and transmembrane TNF and TNF-signal transduction in gastrointestinal diseases with special reference to inflammatory bowel diseases. Z Gastroenterol 40:587–600

    Article  CAS  PubMed  Google Scholar 

  9. Siegel SA et al (1995) The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 7:15–25

    Article  CAS  PubMed  Google Scholar 

  10. Knight DM et al (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30:1443–1453

    Article  CAS  PubMed  Google Scholar 

  11. Scallon BJ et al (1995) Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7:251–259

    Article  CAS  PubMed  Google Scholar 

  12. Luegering A et al (2001) Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathway. Gastroenterology 121:1145–1157

    PubMed  Google Scholar 

  13. Ewe K et al (1993) Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn’s disease. Gastroenterology 105:367–372

    CAS  PubMed  Google Scholar 

  14. Candy S et al (1995) A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 37:674–678

    CAS  PubMed  Google Scholar 

  15. Sandborn WJ, Sutherland L, Pearson DC, May GR, Modigliani R, Prantera C (1999) Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. The Cochrane Library. Update Software, Oxford

    Google Scholar 

  16. Pearson DC et al (2000) Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev 2(Ia):CD000067

    PubMed  Google Scholar 

  17. Tiede I et al (2003) CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 111:1133–1145

    Article  CAS  PubMed  Google Scholar 

  18. Neurath MF, Stange E (2000) Evidenzbasierte Immunsuppression bei chronisch entzündlichen Darmerkrankungen. Dtsch Ärztebl 97:A1977

    Google Scholar 

  19. Fazio VW et al (1989) Stricture-plasty in Crohn’s disease. Ann Surg 210:621–625

    CAS  PubMed  Google Scholar 

  20. Fazio VW et al (1996) Effect of resection margins on the recurrence of Crohn’s disease in the small bowel. Ann Surg 224:563–573

    Article  CAS  PubMed  Google Scholar 

  21. Van Dullemen HM et al (1995) Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109:129–135

    PubMed  Google Scholar 

  22. Targan SR et al (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 337:1029–1035

    Article  CAS  PubMed  Google Scholar 

  23. Schunk K et al (2000) Hydro-MRI in Crohn’s disease: appraisal of disease activity. Invest Radiol 35:431–437

    Google Scholar 

  24. Schunk K et al (2000) Assessment of inflammatory activity in Crohn disease with hydro-MRI. Röfo Fortschr Geb Röntgenstr Neuen Bildgeb Verfahr 172:153–160

    Article  CAS  Google Scholar 

  25. Bartenstein P et al (1997) Central motor processing in Huntington’s disease. A PET study. Brain 120:1553–1567

    Article  PubMed  Google Scholar 

  26. Bicik I et al (1997) Inflammatory bowel disease activity measured by positron-emission tomography. Lancet 350:262

    CAS  Google Scholar 

  27. Neurath MF et al (2002) Non-invasive assessment of Crohn’s disease activity: a comparison of 18F-fluoro-deoxy-glucose-positron emission tomography. Hydromagnetic resonance imaging and granulocyte scintigraphy with labelled antibodies. Am J Gastroenterol 97:1878–1885

    Google Scholar 

  28. Holtmann M et al (2003) Anti-TNF antibodies in the treatment of inflammatory intestinal stenoses in Crohn’s disease. Z Gastroenterol 41:11–17

    Article  CAS  PubMed  Google Scholar 

  29. Jones JH, Lennard-Jones JF (1966) Corticosteroids and corticotropin in the treatment of Crohn’s disease. Gut 7:181–187

    CAS  PubMed  Google Scholar 

  30. Malchow H et al (1984) European cooperative Crohn’s disease study (ECCDS): results of drug treatment. Gastroenterology 86:249–266

    CAS  PubMed  Google Scholar 

  31. Brandt LJ et al (1982) Metronidazole therapy for perineal Crohn’s disease: a follow-up study. Gastroenterology 83:383–387

    CAS  PubMed  Google Scholar 

  32. Bernstein LH et al (1980) Healing of perineal Crohn’s disease with metronidazole. Gastroenterology 79:357–365

    CAS  PubMed  Google Scholar 

  33. Schneider MU et al (1985) Metronidazol in der Behandlung des Morbus Crohn. Dtsch Med Wochenschr 110:1724–1730

    CAS  PubMed  Google Scholar 

  34. Turunen U, Farkkila M, Seppala K (1989) Long-term treatment of perianal or fistulous Crohn’s disease with ciprofloxacin. Scand J Gastroenterol 24:144

    Google Scholar 

  35. Present DH et al (1980) Treatment of Crohn’s disease with 6-mercaptopurine: a long-term randomized double blind study. N Engl J Med 302:981–987

    CAS  PubMed  Google Scholar 

  36. Korelitz BI, Present DH (1985) Favorable effect of 6-mercaptopuine on fistulae of Crohn’s disease. Dig Dis Sci 30:58–64

    CAS  PubMed  Google Scholar 

  37. O’Brien JJ, Bayless TM, Bayless JA (1991) Use of azathioprine or 6-mercaptopurine in the treatment of Crohn’s disease. Gastroenterology 101:39–46

    CAS  PubMed  Google Scholar 

  38. Present DH et al (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340:1398–1405

    Article  CAS  PubMed  Google Scholar 

  39. Sands BE et al (2004) Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 350:934–936

    Google Scholar 

  40. Sandborn WJ et al (2001) An engineered human antibody to TNF (CDP571) for active Crohn’s disease: a randomized, double-blind placebo-controlled trial. Gastroenterology 120:1330–1338

    CAS  PubMed  Google Scholar 

  41. Feagan BG et al (2000) A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn’s disease [abstract]. Gastroenterology 118:A655

    Google Scholar 

  42. Bell SJ et al (2003) Response of fistulating Crohn’s disease to infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther 17:387–393

    Google Scholar 

  43. Van Bodegraven AA et al (2002) Endosonographic evidence of persistence of Crohn’s disease-associated fistulas after infliximab treatment, irrespective of clinical response. Dis Colon Rectum 45:39–45

    Article  PubMed  Google Scholar 

  44. Rasul I et al (2004) Clinical and radiological responses after infliximab treatment for perianal fistulizing Crohn’s disease. Am J Gastroenterol 99:82–88

    Google Scholar 

  45. Marks CG, Ritchie JK, Lockhart-Mummery HE (1981) Anal fistulas in Crohn’s disease. Br J Surg 68:525–527

    CAS  PubMed  Google Scholar 

  46. Bernard D, Morgan S, Tasse D (1986) Selective surgical management of Crohn’s disease of the anus. Can J Surg 29:318–321

    CAS  PubMed  Google Scholar 

  47. Williamson P et al (1995) Twenty year review of the surgical management of perianal Crohn’s disease. Dis Colon Rectum 38:389–392

    CAS  PubMed  Google Scholar 

  48. Nordgren S, Fasth S, Hulten L (1992) Anal fistulas in Crohn’s disease: incidence and outcome of surgical treatment. Int J Colorectal Dis 7:214–218

    CAS  PubMed  Google Scholar 

  49. Williams J et al (1991) Fistula-in-ano in Crohn’s disease. Dis Colon Rectum 34:378–384

    CAS  PubMed  Google Scholar 

  50. White R et al (1990) Seton management of complex anorectal fistulas in patients with Crohn’s disease. Dis Colon Rectum 33:587–589

    CAS  PubMed  Google Scholar 

  51. Pearl RK et al (1993) Role of the seton in the management of anorectal fistulas. Dis Colon Rectum 39:573–577

    Google Scholar 

  52. Scott H, Northover J (1996) Evaluation of surgery for perianal Crohn’s fistulas. Dis Colon Rectum 39:1039–1043

    CAS  PubMed  Google Scholar 

  53. Regueiro M, Mardini H (2003) Treatment of perianal fistulizing Crohn’s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 9:98–103

    Article  PubMed  Google Scholar 

  54. Topstad DR et al (2003) Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn’s disease: a single center experience. Dis Colon Rectum 46:577–583

    Article  PubMed  Google Scholar 

  55. Poritz LS, Rowe WA, Koltun WA (2002) Remicade does not abolish the need for surgery in fistulizing Crohn’s disease. Dis Colon Rectum 45:771–775

    Article  PubMed  Google Scholar 

  56. Broe PO, Bayless TM, Cameron JL (1982) Crohn’s disease: are enteroenteral fistulas an indication for surgery? Surgery 91:249–253

    CAS  PubMed  Google Scholar 

  57. Radcliffe A et al (1988) Anavaginal and rectovaginal fistulas in Crohn’s disease. Dis Colon Rectum 31:94–99

    CAS  PubMed  Google Scholar 

  58. Scott N, Nair A, Hughes L (1992) Anorectal and rectovaginal fistula with Crohn’s disease. Br J Surg 79:1379–1380

    CAS  PubMed  Google Scholar 

  59. Joo JS et al (1998) Endorectal advancement flap in perianal Crohn’s disease. Am Surg 64:147–150

    CAS  PubMed  Google Scholar 

  60. Hesterberg R et al (1993) Treatment of anovaginal fistulas with an anocutaneous flap in patients with Crohn’s disease. Int J Colorectal Dis 1993:51–54

    Google Scholar 

  61. Ozuner G et al (1996) Long-term analysis of the use of transanal rectal advancement flaps for complicated anorectal/vaginal fistulas. Dis Colon Rectum 39:10–14

    CAS  PubMed  Google Scholar 

  62. Hanauer SB, Smith MB (1993) Rapid closure of Crohn’s disease fistulas with continuous intravenous cyclosporin. Am J Gastroenterol 88:646–649

    CAS  PubMed  Google Scholar 

  63. Game X et al (2003) Infliximab treatment of Crohn disease ileovesical fistula. Scand J Gastroenterol 38:1097–1098

    Article  CAS  PubMed  Google Scholar 

  64. Beart F et al (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 348:601–608

    Article  PubMed  Google Scholar 

  65. Keane J et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098–1104

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Markus F. Neurath.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Holtmann, M.H., Neurath, M.F. Anti-TNF strategies in stenosing and fistulizing Crohn’s disease. Int J Colorectal Dis 20, 1–8 (2005). https://doi.org/10.1007/s00384-004-0634-0

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-004-0634-0

Keywords

Navigation